Anthony Michael Joshua
Impact in
- Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Pulmonary and Respiratory Medicine top 0.1%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
Papers in
-
- Prostate Cancer Treatment and Research 106
- Oncology 84
- Cancer Immunotherapy and Biomarkers 45
- CAR-T cell therapy research 21
- Co-authors
- Leila Khoja (16 shared papers)Jeremy Andrew Squire (12 shared papers)Megan Crumbaker (25 shared papers)Maisa Yoshimoto (8 shared papers)Maria Zieleńska (7 shared papers)Andrew John Evans (10 shared papers)Marcus Otho Butler (18 shared papers)Raya Leibowitz‐Amit (13 shared papers)
- Journals
- Annals of Oncology (33 papers)Journal of Clinical Oncology (17 papers)European Journal of Cancer (12 papers)Clinical Cancer Research (11 papers)The Lancet Oncology (9 papers)
- Partner nations
- AustraliaCanadaUnited States
In The Last Decade
Anthony Michael Joshua
266 papers receiving 22.2k citations
Anthony Michael Joshua's Hit Papers
Peers
Comparison fields: 5 of 155
- Oncology 9.5k
- Pulmonary and Respiratory Medicine 8.4k
- Immunology 4.3k
- Cancer Research 2.8k
- Ophthalmology 1.4k
Countries citing papers authored by Anthony Michael Joshua
This map shows the geographic impact of Anthony Michael Joshua's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Michael Joshua with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Michael Joshua more than expected).
Fields of papers citing papers by Anthony Michael Joshua
This network shows the impact of papers produced by Anthony Michael Joshua. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Michael Joshua. The network helps show where Anthony Michael Joshua may publish in the future.
Co-authors
The 25 scholars most cited alongside Anthony Michael Joshua, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 286 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma Hit paper breakdown → | 2013 | 2928 |
| 2 | Enzalutamide in Metastatic Prostate Cancer before Chemotherapy Hit paper breakdown → | 2014 | 2453 |
| 3 | Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial Hit paper breakdown → | 2014 | 1540 |
| 4 | Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer Hit paper breakdown → | 2019 | 1169 |
| 5 | Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma Hit paper breakdown → | 2016 | 905 |
| 6 | [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial Hit paper breakdown → | 2021 | 847 |
| 7 | Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 Hit paper breakdown → | 2019 | 742 |
| 8 | Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma Hit paper breakdown → | 2021 | 670 |
| 9 | Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab Hit paper breakdown → | 2016 | 605 |
| 10 | Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma Hit paper breakdown → | 2016 | 550 |
| 11 | 2017 | 392 | |
| 12 | Effect of Selumetinib vs Chemotherapy on Progression-Free Survival in Uveal Melanoma Hit paper breakdown → | 2014 | 356 |
| 13 | 2018 | 250 | |
| 14 | Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Hit paper breakdown → | 2023 | 240 |
| 15 | 2008 | 233 | |
| 16 | 2016 | 224 | |
| 17 | 2018 | 219 | |
| 18 | Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study Hit paper breakdown → | 2019 | 217 |
| 19 | 2016 | 213 | |
| 20 | PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial Hit paper breakdown → | 2022 | 205 |
About Anthony Michael Joshua
Anthony Michael Joshua is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Ophthalmology and Radiology, Nuclear Medicine and Imaging, having authored 286 papers that have together received 22.6k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (106 papers), Cancer Immunotherapy and Biomarkers (45 papers), Ocular Oncology and Treatments (29 papers), CAR-T cell therapy research (21 papers), Radiopharmaceutical Chemistry and Applications (20 papers), Cancer, Lipids, and Metabolism (19 papers), Cancer Genomics and Diagnostics (18 papers) and Immunotherapy and Immune Responses (15 papers). The work is most often cited by research in Oncology (9.5k citations), Pulmonary and Respiratory Medicine (8.4k citations), Immunology (4.3k citations), Cancer Research (2.8k citations) and Ophthalmology (1.4k citations). Anthony Michael Joshua has collaborated with scholars based in Australia, Canada and United States. Frequent co-authors include Leila Khoja, Jeremy Andrew Squire, Megan Crumbaker, Maisa Yoshimoto, Maria Zieleńska, Andrew John Evans, Marcus Otho Butler, Raya Leibowitz‐Amit, Richard F. Kefford and Jennifer Jane Knox. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, European Journal of Cancer, Clinical Cancer Research and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.